Acesso livre
Acesso livre

Infectologia

Covid-19: nova mutação da variante Delta sob observação atenta no Reino Unido.

20 Out, 2021 | 12:03h

Covid-19: New mutation of Delta variant under close watch in UK – BBC

Estudo RECOVERY | Em pacientes internados com COVID-19, colchicina não reduziu a mortalidade em 28 dias, a permanência no hospital ou o risco de progressão para ventilação mecânica invasiva.

19 Out, 2021 | 12:55h

Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial – The Lancet Respiratory Medicine

Conteúdos relacionados:

Revisão sistemática | Colchicina para tratamento de COVID-19 – Não há benefício para pacientes hospitalizados; evidências inconclusivas para o tratamento de pacientes não internados mostram que “é provável que reduza levemente a necessidade de hospitalização ou morte em 28 dias, em comparação ao placebo.”

19 Out, 2021 | 12:54h

Colchicine for the treatment of COVID‐19 – Cochrane Library

Conteúdos relacionados:

 

Comentário no Twitter

 

Consequências de longo prazo do mau uso de dados sobre ivermectina.

19 Out, 2021 | 12:52h

Long-term consequences of the misuse of ivermectin data – The Lancet Infectious Diseases

Conteúdos relacionados:

Ivermectin: How false science created a Covid ‘miracle’ drug.

Fraudulent ivermectin studies open up new battleground between science and misinformation.

The lesson of ivermectin: meta-analyses based on summary data alone are inherently unreliable.

Ivermectin: Cochrane’s most talked about review so far, ever. Why?

Flawed ivermectin preprint highlights challenges of COVID drug studies.

Systematic review: no evidence to support the use of Ivermectin for treating or preventing COVID-19.

Why was a major study on ivermectin for covid-19 just retracted?

RCT: Ivermectin does not prevent hospitalizations in patients with COVID-19.

Ivermectin for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials – “IVM did not reduce all-cause mortality, length of stay or viral clearance in RCTs in COVID-19 patients with mostly mild disease”.

Ivermectin is the new hydroxychloroquine, take 2 – “Ivermectin shouldn’t be used to treat COVID-19 outside of the context of a well-designed clinical trial”.

Therapeutics and COVID-19 | WHO guideline update advises Ivermectin should only be used to treat COVID-19 within clinical trials

RCT: Ivermectin does not improve time to resolution of symptoms among adults with mild COVID-19

 

Comentário no Twitter

 

Editorial | Preparação para a “doença X”.

19 Out, 2021 | 12:50h

Preparing for “Disease X” – Science

Vacinas da China contra a COVID foram cruciais – agora, a imunidade está diminuindo.

19 Out, 2021 | 12:49h

China’s COVID vaccines have been crucial — now immunity is waning – Nature

Conteúdos relacionados:

[Preprint] Breakthrough SARS-CoV-2 infections in 620,000 U.S. Veterans, February 1, 2021 to August 13, 2021 – “Vaccine protection declined by mid-August 2021, decreasing from 91.9% in March to 53.9%”.

Observational study in Qatar showed the effectiveness of Pfizer vaccine against any SARS-CoV-2 infection dropped to 20% in months 5 through 7 after the second dose, but effectiveness against severe Covid-19 remained high.

Cohort study: Pfizer vaccine effectiveness against any infections declined from 88% during the first month after full vaccination to 47% after 5 months. Vaccine effectiveness against hospital admissions remained high; 87% within 1 month, and 88% at 5 months after full vaccination, with no significant waning.

Editorial | Covid-19 vaccination: evidence of waning immunity is overstated.

COVID vaccine immunity is waning — how much does that matter? – “As debates about booster shots heat up, what’s known about the duration of vaccine-based immunity is still evolving”.

COVID vaccine effects wane over time but still prevent death and severe illness.

Perspective | What we actually know about waning immunity.

Another study shows Pfizer mRNA vaccine immunity is reduced over time.

[Press release – not published yet] Study shows vaccine protection wanes over time, but vaccines still offer good protection against severe disease.

Studies: COVID vaccine protection waning against infection but not hospitalization.

Comissão BJS sobre cirurgia e cuidado perioperatório pós-COVID-19.

19 Out, 2021 | 12:47h

BJS commission on surgery and perioperative care post-COVID-19 – British Journal of Surgery

Conteúdo relacionado: Cohort Study: Effect of COVID-19 pandemic lockdowns on planned cancer surgery for 15 tumor types in 61 countries.

 

Comentário no Twitter

 

M-A | Fatores de risco para infecção invasiva por Candida (IIC) em pacientes críticos – Os fatores de mais alto risco de IIC foram antibióticos de amplo espectro (OR 5,6), transfusão sanguínea (OR 4,9), colonização por Candida (OR 4,7), cateter venoso central (OR 4,7) e nutrição parenteral total (OR 4,6).

19 Out, 2021 | 12:34h

Risk factors for invasive candida infection in critically ill patients – a systematic review and meta-analysis – Chest

Estudo randomizado embasa o uso de heparina em dose terapêutica para pacientes não críticos internados por Covid-19.

18 Out, 2021 | 08:57h

Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial – The BMJ

Comentário: High-dose of readily available blood thinner reduces risk of death for moderately ill COVID-19 patients – St. Michael’s Hospital

Estudos relacionados (alguns resultados conflitantes)

RCT: Therapeutic-dose heparin superior to standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19.

Another meta-analysis suggests standard-dose prophylactic anticoagulation is the best option for patients hospitalized with Covid-19.

M-A: Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19 – According to this analysis, standard-dose prophylactic anticoagulation should be the standard of care for hospitalized patients with COVID-19 who do not have an indication for therapeutic anticoagulation, irrespective of disease severity.

RCT: In noncritically ill patients hospitalized with Covid-19, therapeutic-dose anticoagulation with heparin increased the probability of survival to hospital discharge compared with usual-care thromboprophylaxis.

RCT: In critically ill patients with Covid-19, therapeutic anticoagulation with heparin did not result in improved outcomes compared to usual-care pharmacologic thromboprophylaxis.

RCT: In patients hospitalized with Covid-19 with elevated D-Dimer, a full-dose anticoagulation strategy based on rivaroxaban (full-dose heparins in unstable patients) + rivaroxaban to day 30 was not better than prophylactic anticoagulation and increased bleeding risk.

 

Comentário no Twitter

 

Vacina da J&J contra COVID-19: FDA recomenda dose de reforço para adultos acima de 18 anos pelo menos 2 meses depois da vacinação com dose única.

18 Out, 2021 | 08:55h

Comunicado de imprensa: Johnson & Johnson COVID-19 Vaccine Booster Shot Unanimously Recommended for Emergency Use Authorization by U.S. FDA Advisory Committee

Comentários:

FDA panel endorses booster shot for J&J COVID-19 vaccine – Associated Press

The Johnson & Johnson one-dose vaccine offers good protection now. A booster shot will maximize that, experts say – CNN

FDA advisers recommend J&J Covid-19 vaccine boosters, talk mix and match boosters – CNN

Conteúdo relacionado: [Press release – not published yet] J&J says booster shot at two months provided 75% protection against moderate to severe COVID-19 globally and 94% of such cases in the U.S.

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.